In the Hong Kong stock market, Lai Kai Medicine-B surged by over 40%, with its stock price rising over 120% in the past three days. The company's new drug LAE102 for obesity has had its clinical trial application accepted.
On the news front, the company announced that its new drug LAE102, targeting obesity indications, has had its clinical trial application accepted by regulatory authorities. LAE102 is a monoclonal antibody independently developed by Lai Kai Medicine, specifically targeting ActRIIA. It has shown synergistic effects with GLP-1 combination therapy in obese mouse models, enhancing fat reduction while protecting muscles, indicating its significant potential in the treatment of adult obesity or metabolic diseases.
Huachuang Securities previously pointed out that the globally pioneering ActRIIA monoclonal antibody LAE102, which can increase muscle mass and reduce fat, has the potential to be used in combination with GLP-1RA, offering tremendous market potential and international value. Changcheng Securities also believes that the company's self-developed pipeline, represented by the muscle-building and fat-reducing drug LAE102, has a promising outlook in the preclinical stage, showing optimism for the company's long-term development.

02105

In the morning session, Hong Kong-listed LAEKNA-B surged over 40% as the company's new drug LAE102 for obesity has had its clinical trial application accepted.

Concept stocks related to weight loss have become "money printing machines", with LAEKNA-B's stock price rising by over 120% in three days.